Obesity Today—May 19, 2026

This week’s Obesity update highlights regulatory oversight, advancing metabolic pipelines, early clinical progress, and global access initiatives.

In this Newsletter

Dive deeper

🧬 Innovent mazdutide and obesity pipeline at ADA 2026 [1] [US • 12 May 2026]

https://www.prnewswire.com/news-releases/innovent-to-present-multiple-clinical-and-preclinical-results-of-mazdutide-and-next-generation-obesity–metabolic-pipeline-at-the-2026-ada-scientific-sessions-302769630.html
Context: Assets include mazdutide, IBI3032, IBI3042, IBI3040, and IBI3046 across obesity and metabolic disease.
Key point: Innovent Biologics will present mazdutide data and next-generation obesity pipeline results at ADA 2026.
Implication: Signals pipeline investment and modality expansion.

⚖️ EktaH NKS-3 weight-maintenance data [2] [12 May 2026]

https://www.globenewswire.com/news-release/2026/05/12/3292530/0/en/ektah-shows-50-reduction-in-post-glp-1-weight-rebound-with-novel-obesity-treatment-and-reports-positive-phase-i-data.html
Context: Phase I data include 87+ dosed subjects with no serious adverse events reported to date.
Key point: EktaH said NKS-3 reduced post-semaglutide weight rebound by about 50% in obese mice.
Implication: May influence prescriber choice and payer reviews pending full data.

🚨 Korea GLP-1 obesity drug inspection violations [3] [Korea • 14 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31665
Context: Checks focused on clinics and pharmacies handling tirzepatide injections, the ingredient in Mounjaro.
Key point: Korea’s MFDS found illegal GLP-1 obesity drug sales and record-keeping violations at six of 632 inspected sites.
Implication: Introduces compliance scrutiny that may affect prescribing, dispensing, and access controls.

📈 MetaVia DA-1726 obesity study update [4] [US • 14 May 2026]

https://www.prnewswire.com/news-releases/metavia-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302772529.html
Context: The study is testing titration to 48 mg and 64 mg, with Part 3 data expected in Q4 2026.
Key point: MetaVia dosed the first patient in Phase 1 Part 3 of DA-1726 for obesity.
Implication: May influence prescriber choice and payer reviews pending full data.

🌍 WHO semaglutide and rapid-acting insulin access track [5] [Global • 15 May 2026]

https://healthpolicy-watch.news/new-who-prequalification-track-for-popular-weight-loss-drug-and-fast-acting-insulin-aims-to-accelerate-access/
Context: The semaglutide call is for diabetes management, not obesity treatment.
Key point: WHO called for generic semaglutide and rapid-acting insulin analogue submissions for prequalification.
Implication: May expand screening, initiation, and follow-up at scale.

🌿 Newon cissus extract GLP-1 study [6] [Korea • 15 May 2026]

https://www.mk.co.kr/en/stock/12048897
Context: The randomized, double-blind, placebo-controlled study ran 16 weeks in 248 adults.
Key point: Newon said cissus extract significantly increased GLP-1 secretion in overweight and obese adults.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💼 Korean pharma and biotech Q1 earnings [7] [Korea • 17 May 2026]

https://www.thelec.net/news/articleView.html?idxno=10529
Context: Samsung Biologics, Celltrion, SK Biopharmaceuticals, and Dongkook Pharmaceutical reported record earnings.
Key point: Major Korean pharma and biotech firms posted strong Q1 sales, while profitability diverged.
Implication: Signals pipeline investment and modality expansion.

💪 Harbour BioMed LET003 pre-clinical obesity data [8] [China/Hong Kong • 17 May 2026]

https://www.prnewswire.com/news-releases/harbour-biomed-announces-promising-preclinical-data-for-let003-its-first-ai-enabled-drug-candidate-302774272.html
Context: LET003 is an ACVR2A/2B-targeting monoclonal antibody developed using the Hu-mAtrIx AI platform.
Key point: Harbour BioMed said LET003 enhanced fat reduction and preserved lean mass when combined with semaglutide in mice.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Obesity pipelines are moving beyond GLP-1 monotherapy toward dual agonists, maintenance therapies, amylin, siRNA, and lean mass preservation. [1], [2], [8]
Access pressure is rising, with WHO targeting quality-assured generic semaglutide and insulin pathways for diabetes care in LMICs. [5]
Korea’s inspections show regulators are tightening oversight as GLP-1 demand expands outside traditional medical channels. [3]
Early-stage body-composition claims remain important but need full clinical data before practice-changing conclusions. [2], [4], [8]

📚 View the full Obesity archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is Innovent presenting at ADA 2026?

Innovent plans to present mazdutide data and next-generation obesity/metabolic pipeline results, including oral GLP-1 small molecules, amylin, and INHBE siRNA assets. [1]

What did EktaH report for NKS-3?

EktaH reported about 50% less weight rebound after semaglutide discontinuation in mice, plus early Phase I safety signals with no serious adverse events reported to date. [2]

What did Korea MFDS find in GLP-1 inspections?

MFDS found violations at six of 632 clinics and pharmacies, including prescription-only GLP-1 sales without prescriptions and medical-record issues. [3]

Is WHO prequalifying semaglutide for obesity?

The WHO call described in the source targets semaglutide formulations for diabetes management, alongside rapid-acting insulin analogues. [5]

What is Harbour BioMed’s LET003?

LET003 is an ACVR2A/2B-targeting monoclonal antibody. Harbour BioMed reported pre-clinical data suggesting improved fat reduction and lean mass preservation with semaglutide. [8]

Entities / Keywords

Innovent Biologics, mazdutide, IBI3032, IBI3042, IBI3040, IBI3046, ADA 2026
EktaH, NKS-3, NKS-5, fat taste receptors, CD36, GPR120, SERENITY-1
Korea MFDS, GLP-1, tirzepatide, Mounjaro, semaglutide, Wegovy
MetaVia, DA-1726, vanoglipel, DA-1241, GLP-1/glucagon, MASH
WHO, semaglutide, Ozempic, rapid-acting insulin analogues, prequalification, LMICs
Newon, cissus extract, GLP-1 secretion, DPP-4
Samsung Biologics, Celltrion, SK Biopharmaceuticals, Dongkook Pharmaceutical, Korean pharma
Harbour BioMed, LET003, ACVR2A/2B, Hu-mAtrIx, bimagrumab, lean mass